PMID- 35140486
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 15
DP  - 2022
TI  - Relationship Between Serum Uric Acid-to-Creatinine Ratio and the Risk of 
      Metabolic-Associated Fatty Liver Disease in Patients with Type 2 Diabetes 
      Mellitus.
PG  - 257-267
LID - 10.2147/DMSO.S350468 [doi]
AB  - PURPOSE: To investigate the association between serum uric acid-to-creatinine 
      ratio (SUA/Cr) and the risk of developing metabolic-associated fatty liver 
      disease (MAFLD) in patients with type 2 diabetes mellitus (T2DM). PATIENTS AND 
      METHODS: Overall, 1434 patients with T2DM who were admitted to Hebei General 
      Hospital from January 2019 to December 2019 were selected as the study subjects. 
      According to abdominal ultrasound findings, patients were divided into two 
      groups: MAFLD group and non-MAFLD group. A total of 734 patients were diagnosed 
      with MAFLD. Participants were divided into three study groups according to the 
      SUA/Cr ratio. Chi-square test and one-way analysis of variance were used to 
      perform a comparison between groups. The relationship between SUA/Cr ratio and 
      MAFLD risk was analyzed using correlation analysis and regression analysis. 
      Furthermore, subgroup analyses were performed to verify the robustness of the 
      results. RESULTS: The detection rate of MAFLD in patients with T2DM was 51.2%, 
      and the detection rate of progressive liver fibrosis in T2DM patients with MAFLD 
      was 36.6%. A significantly higher SUA/Cr ratio was seen in the MAFLD group than 
      in the non-MAFLD group. After adjusting for confounding factors, multivariate 
      logistic regression analysis revealed that the SUA/Cr ratio was an independent 
      risk factor for MAFLD development. Stronger correlations were found in 
      participants with a body mass index ranging between 23 and 28 kg/m2, HbA1C >7%, 
      or female sex. CONCLUSION: An elevated SUA/Cr index is independently correlated 
      with an increased risk of MAFLD in Chinese adults with T2DM.
CI  - (c) 2022 Xing et al.
FAU - Xing, Yuling
AU  - Xing Y
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, 050017, 
      People's Republic of China.
AD  - Graduate School of Hebei Medical University, Shijiazhuang, 050017, People's 
      Republic of China.
FAU - Chen, Jinhu
AU  - Chen J
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, 050017, 
      People's Republic of China.
AD  - Graduate School of Hebei Medical University, Shijiazhuang, 050017, People's 
      Republic of China.
FAU - Liu, Jing
AU  - Liu J
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, 050017, 
      People's Republic of China.
AD  - Graduate School of Hebei Medical University, Shijiazhuang, 050017, People's 
      Republic of China.
FAU - Song, Guangyao
AU  - Song G
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, 050017, 
      People's Republic of China.
AD  - Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, 
      050017, People's Republic of China.
FAU - Ma, Huijuan
AU  - Ma H
AUID- ORCID: 0000-0002-4176-5013
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, 050017, 
      People's Republic of China.
AD  - Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, 
      050017, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20220202
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC8818775
OTO - NOTNLM
OT  - SUA/Cr
OT  - metabolic-associated fatty liver disease
OT  - type 2 diabetes
COIS- The authors report no conflicts of interest in this work.
EDAT- 2022/02/11 06:00
MHDA- 2022/02/11 06:01
PMCR- 2022/02/02
CRDT- 2022/02/10 05:33
PHST- 2021/11/20 00:00 [received]
PHST- 2022/01/19 00:00 [accepted]
PHST- 2022/02/10 05:33 [entrez]
PHST- 2022/02/11 06:00 [pubmed]
PHST- 2022/02/11 06:01 [medline]
PHST- 2022/02/02 00:00 [pmc-release]
AID - 350468 [pii]
AID - 10.2147/DMSO.S350468 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2022 Feb 2;15:257-267. doi: 10.2147/DMSO.S350468. 
      eCollection 2022.